• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on pharmacotherapy >State-of-the-art pharmacotherapy for diabetic neuropathy
【24h】

State-of-the-art pharmacotherapy for diabetic neuropathy

机译：糖尿病神经病变的最先进药物治疗

获取原文
获取原文并翻译 | 示例
       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction The global epidemic of diabetes has led to an epidemic of diabetes complications. Diabetic neuropathy is the most common microvascular complication, of which diabetic peripheral neuropathy (DPN) and autonomic neuropathy (AN) are the most prevalent, affecting similar to 50% of patients. DPN results in pain with a poor quality of life and a loss of sensation with an increased risk of foot ulceration. Autonomic neuropathy can cause significant morbidity in a minority and is associated with increased mortality. The cornerstone of treatment to prevent or limit the progression of DPN/AN is multifactorial risk factor modification including treatment of glycemia, lipids and blood pressure. Whilst, there are no FDA-approved disease-modifying therapies, there are a number of therapies to relieve symptoms in DPN and AN. Areas covered The authors discuss current approved therapies for painful diabetic neuropathy and autonomic neuropathy. They also address the potential role of improving risk factors to limit the development and progression of diabetic neuropathy and new pathogenetic and pain-relieving treatments. Expert opinion The FDA-approved Pregabalin and Duloxetine over 25 years ago and Tapentadol, 6 years ago for painful diabetic neuropathy. There are currently no FDA-approved disease-modifying treatments for diabetic neuropathy which has been attributed to inappropriate models of the disease with limited translational capacity and major limitations of trial designs and endpoints in clinical trials.
机译：None

著录项

  • 来源
    《Expert opinion on pharmacotherapy》 |2021年第6期|共14页
  • 作者

    Azmi Shazli; Alam Uazman; Burgess Jamie; Malik Rayaz A.;

  • 作者单位

    Univ Manchester Inst Cardiovasc Sci Manchester Lancs England;

    Univ Manchester Inst Human Dev Div Diabet Endocrinol &

    Gastroenterol Manchester Lancs England;

    Univ Liverpool Inst Life Course &

    Med Sci Dept Cardiovasc &

    Metab Med Liverpool Merseyside;

    Weill Cornell Med Qatar Dept Med Doha Qatar;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 药学;
  • 关键词

  • 入库时间 2022-08-20 18:08:28

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号